With respect to patient safety, in the development work we carry out in order to meet the regulatory requirements, 99% of the different products we work on are brand new products. Establishing safety and demonstrating safety to Health Canada is absolutely key before a product will be administered to a patient.
I think this is why this study here is so key with respect to examining accountability and governance. It's really about understanding how a cut in a certain part of the ecosystem really has downstream ramifications. It really points to the need to take a holistic look at how we're supporting our research. The research we do would not be possible without the great research that's being carried out by CIHR-funded researchers. We benefit from that, but our investment is key to getting it to a clinical trial.
